AnaptysBio Q1 2024 Adj EPS $(1.64) Misses $(1.57) Estimate, Sales $7.180M Beat $3.967M Estimate
Portfolio Pulse from Benzinga Newsdesk
AnaptysBio (NASDAQ:ANAB) reported Q1 2024 adjusted EPS of $(1.64), missing the $(1.57) estimate, but sales of $7.180M exceeded the $3.967M estimate, marking a 422.56% increase from the previous year.
May 09, 2024 | 9:13 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
AnaptysBio reported a Q1 2024 adjusted EPS of $(1.64), missing estimates, but sales of $7.180M beat expectations, showing significant growth.
While the EPS miss might concern some investors, the substantial beat on sales and the impressive year-over-year growth could offset negative sentiment. The mixed results present a neutral short-term outlook as investors weigh the significance of the earnings miss against the strong sales performance.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100